ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Survey Shows That One-Third Of Patients Are Undertreated

April 27, 2012

In Brief: Zelen To Retire As Head Of ECOG Statistical Center; NIH Organizes Genome Research Center

October 20, 1989

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

Congress Mandates NIH Cut PR Costs, Coordinate Spending on Communications

January 31, 2014

Broder: Downward Negotiations Or Coercion? NCI Authorities

June 15, 1990

Targeted Biopsy More Effective At Selecting Men For Active Surveillance, Study Says

May 30, 2014